文献速递治疗药物监测与药物基因组学特殊人群用药

「把剂量用对」再探讨:聚焦生物制剂

"Getting the Dose Right"-Revisiting the Topic With Focus on Biologic Agents.
PubMed 文献 · Clin Pharmacol Ther · 2024-04-28

本文回顾Peck和Cross文章发表近二十年后生物制剂的剂量推荐情况,发现撤药和剂量/标签变更发生率相对较低,提示剂量选择有所改善。但单克隆抗体(MAb)上市后临床经验并不完美,炎症性疾病中疾病负担随时间变化且治疗失败率高,常联用类固醇和免疫抑制剂;肿瘤MAb剂量可能高于所需,导致治疗成本高和不良事件发生。鉴于MAb药代动力学复杂,产品标签应包含替代剂量策略选项,并可能纳入治疗药物监测与剂量个体化。

要点

  • 生物制剂剂量推荐较17年前有所改善,撤药和剂量/标签变更发生率相对较低。
  • 炎症性疾病中MAb治疗失败率高,常联用类固醇和免疫抑制剂,后者有自身安全性问题。
  • 肿瘤MAb剂量可能高于所需,导致治疗成本高和不良事件发生。

核心结论

  • 生物制剂剂量推荐较17年前有所改善,但单克隆抗体上市后临床经验仍不完美,仍需进一步优化。

研究设计与样本

  • 本文为综述,回顾Peck和Cross文章发表近二十年后生物制剂的剂量推荐情况。

主要发现

  • 生物制剂撤药和剂量/标签变更发生率相对较低,提示剂量选择成功度有所提高。
  • 炎症性疾病中疾病负担随时间变化,MAb治疗失败率高,常联用类固醇和免疫抑制剂。
  • 肿瘤MAb剂量可能高于所需,导致治疗成本高和不良事件发生。

关键数值与推荐

  • 产品标签应包含替代剂量策略选项,并可能纳入治疗药物监测与剂量个体化,以改善临床反应并减少抗药抗体(ADA)发生率。

临床怎么用

  • 临床使用MAb时应关注疾病负担变化和联用免疫抑制剂的安全性,考虑治疗药物监测与剂量个体化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nearly two decades after the Peck and Cross article '"Getting the dose right: facts, a blueprint, and encouragements" was published, a review of dose recommendations for biologics shows that the success in getting the dose right appears to have improved given the relatively low incidence of drug withdrawals and dosing/label changes. However, the clinical experience with monoclonal antibodies (MAbs) following approval has been less than perfect. In inflammatory diseases, the disease burden changes with time and high treatment failure rates have been reported. In addition, the use of concomitant steroids and immunosuppressant drugs with MAbs is common. These concomitant agents have their own safety issues and many immunosuppressant agents are not well-tolerated although they have been shown to reduce the incidence of anti-drug antibodies (ADA). This same complexity is seen in MAbs used in oncology as well, although with these agents the doses appear to be higher than needed, which results in high treatment costs and incidence of adverse events. Given the complexity of MAb pharmacokinetics, which makes providing a detailed description of dose options difficult, product labeling should include the options for alternative dose strategies and potentially include the use of therapeutic drug monitoring with dose individualization which have been shown to improve clinical response and reduce the incidence of ADA. So, while the recommended dosing for biologics seems improved over the issues noted 17 years ago, we still have some work to do.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Mould DR, Upton RN. "Getting the Dose Right"-Revisiting the Topic With Focus on Biologic Agents. Clin Pharmacol Ther. 2024. PMID: 38680029. doi:10.1002/cpt.3285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。